(S,R,S)-AHPC-PEG4-Alkyne is a high-purity E3 Ligase Ligand-Linker Conjugate specifically crafted for use in PROTAC (Proteolysis Targeting Chimera) drug discovery research. This versatile compound combines an (S,R,S)-configured AHPC-based VHL ligand, a four-unit polyethylene glycol (PEG4) linker, and a terminal alkyne group for efficient bioorthogonal conjugation via click chemistry. As an essential building block for PROTAC design, it enables targeted protein degradation by recruiting the von Hippel-Lindau (VHL) E3 ubiquitin ligase to a target protein of interest, leading to ubiquitination and subsequent proteasomal degradation. (S,R,S)-AHPC-PEG4-Alkyne empowers researchers to streamline the development of next-generation therapeutics by expanding linker versatility and allowing modular assembly of customized PROTACs. This reagent is ideal for applications in oncology, neurodegenerative disease, and innovative chemical biology research seeking to harness the power of targeted protein degradation.
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
(S,R,S)-AHPC-PEG4-Alkyne is a specialized E3 ligase ligand-linker conjugate engineered for use in the development of PROTACs (Proteolysis Targeting Chimeras) and related targeted protein degradation technologies. The molecule features the high-affinity von Hippel-Lindau (VHL) ligand (AHPC) in its stereochemically defined (S,R,S) configuration, a flexible tetraethylene glycol (PEG4) linker, and an alkyne functional group for versatile conjugation with targeting warheads. Such heterobifunctional molecules are essential to enable next-generation therapeutics and research tools for selective protein knockdown.
Mechanism
(S,R,S)-AHPC-PEG4-Alkyne operates by leveraging the ubiquitin-proteasome system through PROTAC technology. The AHPC moiety specifically recruits the VHL E3 ubiquitin ligase complex, while the PEG4 linker provides spatial flexibility. The terminal alkyne group enables bioorthogonal conjugation, commonly via click chemistry, to a ligand or warhead targeting a protein of interest. When incorporated into a PROTAC molecule, this conjugate brings the E3 ligase into close proximity with the target protein, resulting in its ubiquitination and subsequent degradation by the proteasome. This mechanism allows for the targeted elimination of disease-relevant or previously 'undruggable' proteins.
Applications
(S,R,S)-AHPC-PEG4-Alkyne is widely used in medicinal chemistry and chemical biology for the design and synthesis of PROTACs targeting a variety of proteins, such as kinases, transcription factors, and epigenetic regulators. Its versatile alkyne group supports modular assembly via click chemistry, facilitating the rapid development of custom degraders. Applications include validation of new drug targets, creation of tool compounds for functional genomics, cancer research, neurodegenerative disease studies, and the broader development of targeted protein degradation therapeutics. The compound's structure also enables labeling or imaging studies when conjugated with appropriate probes.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.